SEC Filing Summary: Manhattan Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Manhattan Pharmaceuticals, Inc. on May 31, 2007, reporting events occurring on May 24, 2007. The filing addresses corporate governance actions taken at the company's annual stockholder meeting. Note: The request metadata references "TG THERAPEUTICS, INC.", but the filing text explicitly identifies the registrant as Manhattan Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a stock plan amendment and does not contain financial performance data.
Material Changes
- Stock Option Plan Amendment: Stockholders approved an amendment to the 2003 Stock Option Plan.
- Share Increase: The number of shares available for issuance under the plan was increased from 7,400,000 to 10,400,000.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document is limited to the disclosure of the stock plan amendment and the filing of the amended plan as Exhibit 10.1.
Investor Verification Checklist
- Verify the exact terms of the amended 2003 Stock Option Plan in Exhibit 10.1.
- Confirm the impact of the 3,000,000 share increase on potential future dilution.
- Review subsequent filings for any actual grants made under the expanded plan.